BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges

1. BenevolentAI, a UK-based artificial intelligence (AI) company focused on drug discovery, has announced a significant downsizing of its operations, cutting 30% of its staff.
2. The company is also closing its US site, shifting its focus back to its London headquarters.
3. The decision to downsize and close the US site comes as BenevolentAI faces a looming funding gap, with the company reportedly struggling to secure additional investment.
4. BenevolentAI uses AI to analyze vast amounts of scientific data and identify potential new drugs and treatments, with a focus on diseases such as Parkinson's and Alzheimer's.
5. Despite the setbacks, BenevolentAI remains committed to its mission of using AI to improve drug discovery and development, and is exploring new partnerships and collaborations to support its work.